Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months: a PROBE Multicenter Open-label Randomized Controlled Trial

NCT06723717 is registered in ClinicalTrials.gov with Fondation Ophtalmologique Adolphe de Rothschild as lead sponsor.

NCT NCT06723717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06723717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months: a PROBE Multicenter Open-label Randomized Controlled Trial
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2025
Completion date
September 30, 2028
Enrollment
304 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

delayed cerebral ischemia, ruptured aneurysm of intracranial artery, sah (subarachnoid hemorrhage)